Both targeted therapy (the BRAF- plus MEK-inhibitor combination of dabrafenib plus trametinib [dab/tram]) and checkpoint inhibitor (CPI) immunotherapies (ipilimumab, nivolumab, or pembrolizumab) have shown durable clinical benefit as first-line (1L) adjuvant therapy in BRAF-mutant resected stage III melanoma.1-4 These therapies are now considered the standard of care for adequately resected high-risk melanoma and represent a significant advancement in the treatment of this disease. This evidence concerns the gene MAP2K7 and melanoma.